Abstract
In this video Q&A, we talk to Professor Carlos Caldas about the identification of breast cancer subtypes through molecular profiling, and the clinical implications for diagnosis and treatment.
Highlights
Carlos Caldas is a Professor of Cancer Medicine at the University of Cambridge in the UK, and currently heads the Breast Cancer Functional Genomics Laboratory at the Cancer Research UK Cambridge Institute
It is necessary to decide which adjuvant systemic treatment to give; women are risk stratified into different groups based on whether they are going to benefit from adjuvant therapy, chemotherapy
Correspondence: Carlos.Caldas@cruk.cam.ac.uk Cancer Research UK Cambridge Institute receptor positive breast cancer, and the monoclonal antibody trastuzumab for HER2 positive breast cancer
Summary
It is necessary to decide which adjuvant systemic treatment to give; women are risk stratified into different groups based on whether they are going to benefit from adjuvant therapy, chemotherapy. In the case of hormone therapy and trastuzumab, we have very good predictive tests that can help to assess benefit. We know that women with estrogen receptor negative breast cancer do not benefit from hormone therapy, and those with HER2 negative breast cancer do not benefit from trastuzumab treatment.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
